Skip Navigation


JAC Advance Access originally published online on June 27, 2006
Journal of Antimicrobial Chemotherapy 2006 58(2):452-454; doi:10.1093/jac/dkl254
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/2/452    most recent
dkl254v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cui, Y.
Right arrow Articles by Ji, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cui, Y.
Right arrow Articles by Ji, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Antibacterial activity of YC-20, a new oxazolidinone

Yingjie Cui1,*,{dagger}, Yaxian Dang1, Yushe Yang1,{dagger}, Shuhua Zhang2 and Ruyun Ji1

1 Shanghai Institute of Materia Medica, Shanghai Institute for Biological Science, Chinese Academy of Sciences Shanghai 201203, China 2 Sichuan Industrial Institute of Antibiotics Chengdu 610051, China

Received 2 December 2005; returned 24 February 2006; revised 15 May 2006; accepted 26 May 2006

*Corresponding author. E-mail: cuiyingjie{at}yahoo.com

Objectives and methods: YC-20 is a novel oxazolidinone that has targeted activity against Gram-positive bacteria. The in vitro activity of YC-20 and 6 comparators against 522 clinical isolates of Gram-positive species was determined.

Results: YC-20 is a potent oxazolidinone with all isolates tested displaying MIC50 and MIC90 values of <0.5 and 2 mg/L, respectively. MICs of YC-20 for all isolates tested, with the exception of methicillin-susceptible Staphylococcus epidermidis, were similar or lower than those of linezolid.

Conclusions: This study suggests a potential new antibiotic for the treatment of infections with Gram-positive bacteria.

Results: YC-20 is a potent oxazolidinone with all isolates tested displaying MIC50 and MIC90 values of <0.5 and 2 mg/L, respectively. MICs of YC-20 for all isolates tested, with the exception of methicillin-susceptible Staphylococcus epidermidis, were similar or lower than those of linezolid.

Conclusions: This study suggests a potential new antibiotic for the treatment of infections with Gram-positive bacteria.

Keywords: antibiotics , Gram-positive , linezolid


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.